Aerocrine launches a new fully portable hand-held device to measure airway inflammation in asthma

SOLNA, Sweden – 11 September, 2013 - Aerocrine AB (OMX Nordic Exchange: AERO) is
pleased to announce the launch of NIOX VERO®, a new, fully portable hand-held
point-of-care device for the measurement of airway inflammation, such as asthma.
Aerocrine introduces the new device in conjunction with the European Respiratory
Society (ERS) annual meeting in Barcelona, September 7-11, 2013.  NIOX VERO® was
developed in collaboration between Aerocrine and Panasonic Healthcare Co.,Ltd.
NIOX VERO® is a new and upgraded version of the gold standard for measurement of
Fractional exhaled Nitric Oxide (FeNO), a validated and clinically proven method
for assessing allergic airway inflammation such as asthma. NIOX VERO® provides
accurate, reproducible and rapid measurement results. The NIOX VERO® has an
onboard, rechargeable battery, upgraded software, wireless technology, patient
journaling and has a useful life of 15,000 tests or 5 years compared to its
predecessors (NIOX MINO®) 3,000 tests or 3 years.

The CE-marked device used to measure airway inflammation - an underlying cause
of inflammatory airway diseases – helps physicians to improve patient outcomes
and reduce healthcare expenditures. The product is a complement to the Aerocrine
product portfolio and will be initially introduced in selected market segments
in Q4 2013 (Sweden, United Kingdom and Germany). The objective of this initial
introduction is to conduct a real-life handling test of this highly innovative
device in the daily practice of a limited number of demonstration sites. Further
introduction in the remaining European countries is expected during spring 2014.
Among the benefits of NIOX VERO, physicians will have more objective insights
into treatment efficacy and can better predict a patients’ response to therapy
and the risk of an asthma relapse. Moreover, physicians will be able to identify
patient non-compliance with medications, and can adjust the dose of medication
based on individual patients’ needs. By using NIOX VERO doctors can measure the
underlying inflammation that causes asthma within a few minutes directly in
their offices.

Asthma is a chronic disease affecting millions including many children.
Aerocrine’s NIOX products are created to help physicians identify patients that
will respond to the optimal therapy. Patients are different, requiring different
treatments and dosages. Therefore, airway inflammatory disease management and
control can be significantly improved through ‘personalized’ monitoring of the
airway inflammation rather than just following symptoms and assessing lung
function.

About asthma
Asthma is a chronic inflammatory disease of the airways characterized by
symptoms including wheezing, cough and shortness of breath. The disease affects
more than 300 million people around the world, many of whom are children. Asthma
is a complex disease for which there is no cure. Current therapy is focused on
controlling the disease.

For more information, contact:
Scott Myers, Chief Executive Officer, Aerocrine AB, Phone: +46 768 788 379
About Aerocrine
Aerocrine AB is a medical products company focused on improved management and
care of patients with inflammatory airway diseases such as Asthma. Within this
sector, Aerocrine is the world leader. Aerocrine markets NIOX MINO®, which
enables fast and reliable point-of-care measurement of airway inflammation. This
product plays a critical role in more effective diagnosis, treatment and follow
-up of patients affected with inflammatory airway diseases. Aerocrine is based
in Sweden with subsidiaries in the US, Germany, Switzerland and the UK.
Aerocrine shares have been listed on the Stockholm Stock Exchange since 2007
(AERO-B.ST). For more information please visit www.aerocrine.com and
www.niox.com.

Aerocrine may be required to disclose the information provided herein pursuant
to the Securities Markets Act and/or the Financial Instruments Trading Act. The
information was submitted for publication at 08:00 am on September 11, 2013.